Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy
Circulation · 09.01.2024 · 149 (2) · 107-123
DOI: 10.1161/circulationaha.123.065987 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Circulation, erschienen am 09.01.2024. Verfasst von Constantin-Cristian Topriceanu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.-C.T., A.C.P., C.Y.H.). UCL Institute of Cardiovascular S…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute, British Heart Foundation.
Abstract (Originalsprache)
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease because penetrance (proportion of sarcomere or sarcomere-related P/LP variant carriers who develop disease) is variable, age dependent, and not reliably predicted. METHODS: A systematic search of the literature was performed. We used random-effects generalized linear mixed model meta-analyses to contrast the cross-sectional prevalence and penetrance of sarcomere or sarcomere-related genes in 2 different contexts: clinically-based studies on patients and families with HCM versus population or community-based studies. Longitudinal family/clinical studies were additionally analyzed to investigate the rate of phenotypic conversion from subclinical to overt HCM during follow-up. RESULTS: In total, 455 full-text manuscripts and articles were assessed. In family/clinical studies, the prevalence of sarcomere variants in patients diagnosed with HCM was 34%. The penetrance across all genes in nonproband relatives carrying P/LP variants identified during cascade screening was 57% (95% CI, 52%–63%), and the mean age at HCM diagnosis was 38 years (95% CI, 36%–40%). Penetrance varied from ≈32% for MYL3 (myosin light chain 3) to ≈55% for MYBPC3 (myosin-binding protein C3), ≈60% for TNNT2 (troponin T2) and TNNI3 (troponin I3), and ≈65% for MYH7 (myosin heavy chain 7). Population-based genetic studies demonstrate that P/LP sarcomere variants are present in the background population but at a low prevalence of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.-C.T., A.C.P., C.Y.H.). UCL Institute of Cardiovascular Science (C.-C.T., J.C.M., G.C.) and UCL MRC Unit for Lifelong Health an…
ORCID-Profile: Constantin-Cristian Topriceanu, Alexandre C Pereira, Gabriella Captur, Carolyn Y Ho
Förderung
- NHLBI NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute
- British Heart Foundation
- Barts Charity
Zitieren
APA
Topriceanu, C. C., Pereira, A. C., Moon, J. C., Captur, G., & Ho, C. Y. (2024). Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy. Circulation, 149(2), 107-123. https://doi.org/10.1161/circulationaha.123.065987
Vancouver
Topriceanu CC, Pereira AC, Moon JC, Captur G, Ho CY. Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy. Circulation. 2024;149(2):107-123. doi:10.1161/circulationaha.123.065987
BibTeX
@article{Topriceanu2024,
author = {Topriceanu, Constantin-Cristian and Pereira, Alexandre C and Moon, James C and Captur, Gabriella and Ho, Carolyn Y},
title = {Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy},
journal = {Circulation},
year = {2024},
volume = {149},
number = {2},
pages = {107--123},
doi = {10.1161/circulationaha.123.065987}
}
EUVIMED